Zogenix files for $90M IPO

After gathering a $200 million mix of venture funding and debt finance, San Diego-based Zogenix has filed an IPO intended to raise $90 million. The biotech company does have a product on the market: A needle-free device it's using to deliver a migraine therapy. And it has a pain therapy in late-stage development. Biotech IPOs haven't been warmly received by Wall Street this year. But the 2010 record is still better than 2009, when the public market was frozen to new entries. Zogenix dropped a planned offering back in 2008 as the market headed south. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.